CommCore CEO Andrew Gilman was recently quoted in an article published in PR News, Kodak Pivots from Photo to Pharma, where he provides commentary on Kodak’s new business move.
Andy Gilman, president and CEO of CommCore Consulting Group, says Kodak can prepare for choppy waters by foreseeing probable lines of inquiry from stakeholders. Gilman’s concerns echo those of Fadia: “The bigger questions will be: Why Kodak? Why not contract with generic pharmaceutical companies that have a track record dealing with ingredients? Was this a contract awarded as a result of lobbying or political influence?”
Leave a Reply
You must be logged in to post a comment.